Innovative Drug Discovery Strategies are Critical to the Growth of Pharmaceutical...

Innovative Drug Discovery Strategies are Critical to the Growth of Pharmaceutical R&D Productivity

DUBLIN, Ireland--(Business Wire)--
Research and Markets
(http://www.researchandmarkets.com/reports/c88202) has announced the
addition of new Decision Resources report: Navigating the Drug
Discovery Landscape: A Strategic Overview of Pharmaceutical R&D to
their offering.

Pharmaceutical companies must find successful strategies for
future drug discovery. Increased market pressures, looming drug patent
expirations, and dramatically increasing drug development costs have
caused pharmaceutical companies to search for new ways to increase R&D
productivity. To improve their output of NMEs per year, companies are
reshaping their operational infrastructure and relying on new
technologies to stay competitive.

Get the Answers You Need to Shape Your Strategy:

- Companies must decide how to take advantage of new technologies
and devise new strategies to improve drug discovery. What corporate
changes are being made at some of the largest pharmaceutical companies
to change their R&D infrastructure? How will theses changes speed the
time from discovery to approval? What reforms are needed to accelerate
the clinical trials system?

- The pharmaceutical industry has adopted a spectrum of
high-throughput and high-content technologies for lead and target
identification. How are these approaches being applied to drug
discovery and development, and how will these technologies increase
the number of compounds screened annually?

- Several pharmaceutical companies are tapping external sources
for innovation: What companies have created partnerships with U.S.
universities?

Scope:

- Overview: Innovative drug discovery strategies are critical to
the growth of pharmaceutical R&D productivity; increase output of NMEs
needed to justify billions spent on development.

- High-throughput and high-content technologies: decrease cycle
times and costs to increase productivity; lead identification
technologies produce approved drugs; microarray technologies used in
basic research; toxicity prediction using in vitro signature
profiling; patient-specific therapies play a dominant role as
translational research ties mechanism of action and efficacy to
biomarkers; major reforms expected in the U.S. clinical trials system.

- Review of organizational and operational strategies: team
approach to drug discovery and development at GSK is based on
interdisciplinary, autonomous Centers for Excellence in Drug Discovery
(CEDDs); Merck decentralizes R&D to extend responsibilities to its
satellite facilities; Disease Biology Area Leadership Teams at Roche
progress leads from early discovery through medical proof-of-concept;
Novartis Institutes for BioMedical Research focus on disease-relevant
molecular pathways; Teamwork at Wyeth is based on performance metrics.

- External sources of innovation: pharmaceutical companies
establish research centers near academic research sites; corporate
partnerships with biotech companies produces new sources for leads;
venture capital firms help companies tap into innovation.

Companies Mentioned:

- AstraZeneca

- Bayer

- Biogen Idec

- Bristol-Myers Squibb

- Curagen

- DiaDexus

- Eli Lilly

- Genentech

- GlaxoSmithKline

- Human Genome Sciences

- Johnson & Johnson

- Lexicon Pharmaceuticals

- Merck

- Merck Frosst Centre for Therapeutic Research

- Merck Research Laboratories

- Merck Sharp & Dohme Research Laboratories

- Millennium Pharmaceuticals

- Myriad Genetics

- Myriad Pharmaceuticals

- Novartis

- Pfizer

- Roche

- Rosetta Inpharmatics

- Sanofi -Aventis

- Schering-Plough

- Sirna Therapeutics

- Wyeth

For more information visit
http://www.researchandmarkets.com/reports/c88202

Research and Markets
Laura Wood, Senior Manager
Fax: +353 1 4100 980
press@researchandmarkets.com

Copyright Business Wire 2008